Content

Welcome to the CJU website » LOG IN

Details

How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer
Division of Urology, McMaster Institute of Urology, Hamilton, Ontario, Canada
Aug 2016 (Vol. 23, Issue 4, Pages( 8388 - 8394)
PMID: 27544566

Abstract

Text-Size + 

  • Abiraterone acetate (AA) is a selective irreversible inhibitor of CYP 17, a key enzyme in androgen biosynthesis. The efficacy and safety of AA in improving survival and quality of life in metastatic castration resistant prostate cancer (mCRPC) has been demonstrated in two landmark clinical trials (COU-AA-301 and COU-AA-302). This article will review the rationale, pharmacology, clinical indications and contraindications, administration, and adverse effects of AA administration in mCRPC.

Current Issue

August 2017, Vol.24 No.4
canadian journal of urology mobile

canadian journal of urology